A drug utilization study (DUS) of alirocumab in Europe to assess the effectiveness of the dosing recommendation to avoid very low LDL-C levels

First published 17/10/2017

Last updated 14/03/2024

EU PAS number:

EUPAS21314

Study

Finalised

Download as PDF

Documents

Study protocol

Initial protocol

rdct-obs14697-16-1-1-pass-amended-protocol02-PDFA

English (839.92 KB - PDF)View document

Study results

Study results

rdct-obs14697-CSR synopsis-PDFA

English (331.56 KB - PDF)View document

Study report

Other information